IL2 and melanoma: In addition, Knox et al. reported that treatment with a selective HDAC6i (nexturastat A) increased IFN-γ and IL-2 expression in the SM1 murine melanoma model and improved the TME to maximize the effects of anti-PD-1 therapy162.